Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers

Yosuke Osawa, Ekumi Kojika, Koji Nishikawa, Masamichi Kimura, Shigenori Osakaya, Hiromi Miyauchi, Tatsuya Kanto, Yutaka Kawakami, Kiminori Kimura

Research output: Contribution to journalArticle

Abstract

Immune checkpoint blockade with specific antibodies can accelerate anti-tumor immunity, resulting in clinical responses in patients with various types of cancer. However, these antibodies achieve only partial tumor regression. Thus, a wide variety of treatment combinations based on programmed death-ligand 1 (PD-L1) pathway inhibition are under development to enhance such therapeutic effects. In this study, the effects of combination treatment using PRI-724, a selective inhibitor of CBP/β-catenin, and an anti-PD-L1 antibody were examined in a mouse model of colon cancer liver metastasis. Mice were inoculated with SL4 colon cancer cells to produce metastatic liver tumors. The combination treatment resulted in regression of tumor growth, whereas monotherapy with each treatment individually failed to exhibit any anti-tumor activity. In addition, co-administration of the inhibitor and antibody induced CD8 + CD44 low CD62L low cells and interferon (IFN)-γ production in CD8 + T-cells in the liver compared with that in control mice. Administration of an anti-CD8 antibody mitigated the anti-tumor effects of the combined treatment of PRI-724 and anti-PD-L1 antibody. In conclusion, targeting CBP/β-catenin, combined with PD-1/ PD-L1 immune checkpoint blockade, shows potential as a new therapeutic strategy for treating liver metastasis during colon cancer.

Original languageEnglish
Pages (from-to)3013-3026
Number of pages14
JournalOncotarget
Volume10
Issue number32
Publication statusPublished - 2019 Apr 30

Fingerprint

Catenins
Cyclic AMP Response Element-Binding Protein
Protein Binding
Colonic Neoplasms
Carrier Proteins
Cell Death
Ligands
Liver
Growth
Neoplasms
Antibodies
CREB-Binding Protein
CD274 Antigen
Therapeutics
Neoplasm Metastasis
Therapeutic Uses
Liver Neoplasms
Interferons
Anti-Idiotypic Antibodies
Immunity

Keywords

  • CBP
  • Colon cancer
  • Metastatic liver cancer
  • PD-L1
  • β-catenin

ASJC Scopus subject areas

  • Oncology

Cite this

Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers. / Osawa, Yosuke; Kojika, Ekumi; Nishikawa, Koji; Kimura, Masamichi; Osakaya, Shigenori; Miyauchi, Hiromi; Kanto, Tatsuya; Kawakami, Yutaka; Kimura, Kiminori.

In: Oncotarget, Vol. 10, No. 32, 30.04.2019, p. 3013-3026.

Research output: Contribution to journalArticle

Osawa, Y, Kojika, E, Nishikawa, K, Kimura, M, Osakaya, S, Miyauchi, H, Kanto, T, Kawakami, Y & Kimura, K 2019, 'Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers', Oncotarget, vol. 10, no. 32, pp. 3013-3026.
Osawa, Yosuke ; Kojika, Ekumi ; Nishikawa, Koji ; Kimura, Masamichi ; Osakaya, Shigenori ; Miyauchi, Hiromi ; Kanto, Tatsuya ; Kawakami, Yutaka ; Kimura, Kiminori. / Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers. In: Oncotarget. 2019 ; Vol. 10, No. 32. pp. 3013-3026.
@article{d955170b16d546d7acbd74296fe8baaf,
title = "Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers",
abstract = "Immune checkpoint blockade with specific antibodies can accelerate anti-tumor immunity, resulting in clinical responses in patients with various types of cancer. However, these antibodies achieve only partial tumor regression. Thus, a wide variety of treatment combinations based on programmed death-ligand 1 (PD-L1) pathway inhibition are under development to enhance such therapeutic effects. In this study, the effects of combination treatment using PRI-724, a selective inhibitor of CBP/β-catenin, and an anti-PD-L1 antibody were examined in a mouse model of colon cancer liver metastasis. Mice were inoculated with SL4 colon cancer cells to produce metastatic liver tumors. The combination treatment resulted in regression of tumor growth, whereas monotherapy with each treatment individually failed to exhibit any anti-tumor activity. In addition, co-administration of the inhibitor and antibody induced CD8 + CD44 low CD62L low cells and interferon (IFN)-γ production in CD8 + T-cells in the liver compared with that in control mice. Administration of an anti-CD8 antibody mitigated the anti-tumor effects of the combined treatment of PRI-724 and anti-PD-L1 antibody. In conclusion, targeting CBP/β-catenin, combined with PD-1/ PD-L1 immune checkpoint blockade, shows potential as a new therapeutic strategy for treating liver metastasis during colon cancer.",
keywords = "CBP, Colon cancer, Metastatic liver cancer, PD-L1, β-catenin",
author = "Yosuke Osawa and Ekumi Kojika and Koji Nishikawa and Masamichi Kimura and Shigenori Osakaya and Hiromi Miyauchi and Tatsuya Kanto and Yutaka Kawakami and Kiminori Kimura",
year = "2019",
month = "4",
day = "30",
language = "English",
volume = "10",
pages = "3013--3026",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "32",

}

TY - JOUR

T1 - Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers

AU - Osawa, Yosuke

AU - Kojika, Ekumi

AU - Nishikawa, Koji

AU - Kimura, Masamichi

AU - Osakaya, Shigenori

AU - Miyauchi, Hiromi

AU - Kanto, Tatsuya

AU - Kawakami, Yutaka

AU - Kimura, Kiminori

PY - 2019/4/30

Y1 - 2019/4/30

N2 - Immune checkpoint blockade with specific antibodies can accelerate anti-tumor immunity, resulting in clinical responses in patients with various types of cancer. However, these antibodies achieve only partial tumor regression. Thus, a wide variety of treatment combinations based on programmed death-ligand 1 (PD-L1) pathway inhibition are under development to enhance such therapeutic effects. In this study, the effects of combination treatment using PRI-724, a selective inhibitor of CBP/β-catenin, and an anti-PD-L1 antibody were examined in a mouse model of colon cancer liver metastasis. Mice were inoculated with SL4 colon cancer cells to produce metastatic liver tumors. The combination treatment resulted in regression of tumor growth, whereas monotherapy with each treatment individually failed to exhibit any anti-tumor activity. In addition, co-administration of the inhibitor and antibody induced CD8 + CD44 low CD62L low cells and interferon (IFN)-γ production in CD8 + T-cells in the liver compared with that in control mice. Administration of an anti-CD8 antibody mitigated the anti-tumor effects of the combined treatment of PRI-724 and anti-PD-L1 antibody. In conclusion, targeting CBP/β-catenin, combined with PD-1/ PD-L1 immune checkpoint blockade, shows potential as a new therapeutic strategy for treating liver metastasis during colon cancer.

AB - Immune checkpoint blockade with specific antibodies can accelerate anti-tumor immunity, resulting in clinical responses in patients with various types of cancer. However, these antibodies achieve only partial tumor regression. Thus, a wide variety of treatment combinations based on programmed death-ligand 1 (PD-L1) pathway inhibition are under development to enhance such therapeutic effects. In this study, the effects of combination treatment using PRI-724, a selective inhibitor of CBP/β-catenin, and an anti-PD-L1 antibody were examined in a mouse model of colon cancer liver metastasis. Mice were inoculated with SL4 colon cancer cells to produce metastatic liver tumors. The combination treatment resulted in regression of tumor growth, whereas monotherapy with each treatment individually failed to exhibit any anti-tumor activity. In addition, co-administration of the inhibitor and antibody induced CD8 + CD44 low CD62L low cells and interferon (IFN)-γ production in CD8 + T-cells in the liver compared with that in control mice. Administration of an anti-CD8 antibody mitigated the anti-tumor effects of the combined treatment of PRI-724 and anti-PD-L1 antibody. In conclusion, targeting CBP/β-catenin, combined with PD-1/ PD-L1 immune checkpoint blockade, shows potential as a new therapeutic strategy for treating liver metastasis during colon cancer.

KW - CBP

KW - Colon cancer

KW - Metastatic liver cancer

KW - PD-L1

KW - β-catenin

UR - http://www.scopus.com/inward/record.url?scp=85065773678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065773678&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85065773678

VL - 10

SP - 3013

EP - 3026

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 32

ER -